HKSE - Delayed Quote HKD

Laekna, Inc. (2105.HK)

21.250
+1.790
+(9.20%)
As of 3:20:56 PM GMT+8. Market Open.
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
288,649
288,649
305,893
393,314
225,029
Operating Income
-288,649
-288,649
-305,893
-393,314
-225,029
Net Non Operating Interest Income Expense
34,621
34,621
12,261
-566
-513
Pretax Income
-254,296
-254,296
-368,814
-781,594
-748,964
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-254,296
-254,296
-368,814
-781,594
-748,964
Diluted NI Available to Com Stockholders
-254,296
-254,296
-368,814
-781,594
-748,964
Basic EPS
0.55
-0.71
-1.68
-20.04
-1.92
Diluted EPS
0.55
-0.71
-1.68
-20.04
-1.92
Basic Average Shares
356,338
357,626
219,592
39,010.035
390,100.350
Diluted Average Shares
356,338
357,626
219,592
390,100.350
390,100.350
Total Operating Income as Reported
-251,272
-251,272
-295,877
-393,149
-225,610
Rent Expense Supplemental
--
--
--
1,844
868
Total Expenses
288,649
288,649
305,893
393,314
225,029
Net Income from Continuing & Discontinued Operation
-254,296
-254,296
-368,814
-781,594
-748,964
Normalized Income
-254,296
-254,296
-299,888
-398,233
-226,532
Interest Income
37,645
37,645
13,988
823
409
Interest Expense
3,024
3,024
1,727
1,389
922
Net Interest Income
34,621
34,621
12,261
-566
-513
EBIT
-251,272
-251,272
-367,087
-780,205
-748,042
EBITDA
-246,003
-246,003
-361,754
-773,538
-742,216
Reconciled Depreciation
5,269
5,269
5,333
6,667
5,826
Net Income from Continuing Operation Net Minority Interest
-254,296
-254,296
-368,814
-781,594
-748,964
Total Unusual Items Excluding Goodwill
0
0
-68,926
-383,361
-522,432
Total Unusual Items
0
0
-68,926
-383,361
-522,432
Normalized EBITDA
-246,003
-246,003
-292,828
-390,177
-219,784
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 6/29/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6855.HK Ascentage Pharma Group International
58.100
+4.87%
 
2142.HK HBM Holdings Limited
8.380
+5.28%
 
9966.HK Alphamab Oncology
8.190
+2.76%
 
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
345.000
+1.95%
 
9995.HK RemeGen Co., Ltd.
45.950
-0.11%
 
2171.HK CARsgen Therapeutics Holdings Limited
19.720
+2.71%
 
2256.HK Abbisko Cayman Limited
10.220
+6.57%
 
9688.HK Zai Lab Limited
29.650
0.00%
 
2696.HK Shanghai Henlius Biotech, Inc.
48.550
+6.47%
 
1167.HK JACOBIO-B
5.580
+9.20%